Trial Profile
Multicenter Study to Explore the Impact of Florbetaben (FBB) in Change of Diagnosis in Patients Who Are Evaluated for AD and in Whom Lumbar Puncture is Contraindicated or CSF Results Are Ambiguous
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Florbetaben F18 (Primary)
- Indications Alzheimer's disease
- Focus Diagnostic use
- Sponsors Life Molecular Imaging; Piramal Imaging
- 08 Nov 2016 Status changed from recruiting to completed.
- 14 Oct 2015 New trial record